Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues.
Genomic and proteomic analysis of normal and cancer tissues has yielded abundant molecular information for potential biomarker and therapeutic targets. Considering potential advantages in accessibility to pharmacological intervention, identification of targets resident on the vascular endothelium within tumors is particularly attractive. By employing mass spectrometry (MS) as a tool to identify proteins that are over-expressed in tumor-associated endothelium relative to normal cells, we aimed to discover targets that could be utilized in tumor angiogenesis cancer therapy. We developed proteomic methods that allowed us to focus our studies on the discovery of cell surface/secreted proteins, as they represent key antibody therapeutic and biomarker opportunities. First, we isolated endothelial cells (ECs) from human normal and kidney cancer tissues by FACS using CD146 as a marker. Additionally, dispersed human colon and lung cancer tissues and their corresponding normal tissues were cultured ex-vivo and their endothelial content were preferentially expanded, isolated and passaged. Cell surface proteins were then preferentially captured, digested with trypsin and subjected to MS-based proteomic analysis. Peptides were first quantified, and then the sequences of differentially expressed peptides were resolved by MS analysis. A total of 127 unique non-overlapped (157 total) tumor endothelial cell over-expressed proteins identified from directly isolated kidney-associated ECs and those identified from ex-vivo cultured lung and colon tissues including known EC markers such as CD146, CD31, and VWF. The expression analyses of a panel of the identified targets were confirmed by immunohistochemistry (IHC) including CD146, B7H3, Thy-1 and ATP1B3. To determine if the proteins identified mediate any functional role, we performed siRNA studies which led to previously unidentified functional dependency for B7H3 and ATP1B3.
Celera, Alameda, California, United States of America.
Mehdi
M
Mesri
Charlie
C
Birse
Jenny
J
Heidbrink
Kathy
K
McKinnon
Erin
E
Brand
Candy Lee
CL
Bermingham
Brian
B
Feild
William
W
Fitzhugh
Tao
T
He
Steve
S
Ruben
Paul A
PA
Moore
D060887:B7 Antigens / Q000235:genetics / Q000378:metabolism*; D051929:CD146 Antigen / Q000378:metabolism; D003110:Colonic Neoplasms / Q000378:metabolism; D004730:Endothelium, Vascular / Q000473:pathology / Q000503:physiopathology; D055785:Gene Knockdown Techniques; D061307:Human Umbilical Vein Endothelial Cells / Q000378:metabolism*; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D020543:Proteome / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics; D000254:Sodium-Potassium-Exchanging ATPase / Q000235:genetics / Q000378:metabolism*; D053719:Tandem Mass Spectrometry; D014407:Tumor Cells, Cultured
C519304:ATP1B3 protein, human; D060887:B7 Antigens; D051929:CD146 Antigen; C423237:CD276 protein, human; C497902:MCAM protein, human; D020543:Proteome; D034741:RNA, Small Interfering; D000254:Sodium-Potassium-Exchanging ATPase